Trials / Completed
CompletedNCT00592475
A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients
A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Assess the Safety and Effects of Intravenous Conivaptan on the Hepatic Hemodynamic Response in Stable Euvolemic or Hypervolemic Cirrhotic Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Cumberland Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety of IV conivaptan in stable euvolemic or hypervolemic cirrhotic patients, and to characterize the effects of IV conivaptan on the hepatic hemodynamic response in patients with cirrhosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | conivaptan | IV |
| DRUG | Placebo | IV |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2008-01-14
- Last updated
- 2014-05-15
- Results posted
- 2010-09-28
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT00592475. Inclusion in this directory is not an endorsement.